Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $60.89 Consensus PT from Analysts
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month […]
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month […]
